NR3C1 and focal segmental glomerulosclerosis: Finally, and of major clinical relevance, we report the first clinical data in three nephrotic patients with primary FSGS or MCD, all treated successfully on a compassionate-use basis with the partial GR antagonist, mifepristone [15].